MUSOLINO, Antonino
 Distribuzione geografica
Continente #
NA - Nord America 1405
EU - Europa 920
AS - Asia 385
Continente sconosciuto - Info sul continente non disponibili 20
AF - Africa 2
SA - Sud America 2
Totale 2734
Nazione #
US - Stati Uniti d'America 1393
CN - Cina 333
SE - Svezia 238
DE - Germania 220
IT - Italia 195
FI - Finlandia 92
UA - Ucraina 55
IN - India 30
AT - Austria 20
BE - Belgio 20
IE - Irlanda 18
A1 - ???statistics.table.value.countryCode.A1??? 16
GB - Regno Unito 15
PL - Polonia 13
CA - Canada 12
NL - Olanda 12
TR - Turchia 11
FR - Francia 10
IR - Iran 6
EU - Europa 4
CZ - Repubblica Ceca 3
CH - Svizzera 2
CL - Cile 2
ES - Italia 2
KR - Corea 2
RO - Romania 2
SC - Seychelles 2
VN - Vietnam 2
IL - Israele 1
LU - Lussemburgo 1
MK - Macedonia 1
SI - Slovenia 1
Totale 2734
Città #
Chandler 483
Beijing 199
Princeton 149
Ann Arbor 140
Bremen 103
Des Moines 82
Helsinki 64
Jacksonville 59
Grafing 57
Wilmington 55
Parma 38
Dearborn 32
Nanjing 25
San Mateo 22
Vienna 20
Shenyang 16
Woodbridge 15
Brussels 14
Fairfield 14
Jinan 13
Ardea 12
Fremont 12
Rio Saliceto 12
Borås 11
Rome 10
Ashburn 9
Izmir 9
Hebei 8
Milan 8
Nanchang 8
Rockville 8
Augusta 7
Falls Church 7
Norwalk 7
Tianjin 7
Changsha 6
Redwood City 6
Seattle 6
Taiyuan 6
Toronto 6
Ardabil 5
Boardman 5
Hefei 5
Houston 5
Kunming 5
Leawood 5
Dublin 4
Guangzhou 4
Huizen 4
Shenzhen 4
Zhengzhou 4
Andover 3
Bologna 3
Brooklyn 3
Jiaxing 3
Monmouth Junction 3
Pavia 3
Wenzhou 3
Auburn Hills 2
Capriate San Gervasio 2
Daejeon 2
Dong Ket 2
Haikou 2
Hangzhou 2
Kocaeli 2
Madrid 2
Menlo Park 2
Mountain View 2
Naples 2
Ningbo 2
Ravenna 2
Redmond 2
Reggio Nell'emilia 2
Rottofreno 2
San Giovanni Rotondo 2
Taizhou 2
Waanrode 2
Abbiategrasso 1
Bangalore 1
Bastiglia 1
Brno 1
Campogalliano 1
Cornaredo 1
Fuzhou 1
Gambettola 1
Geislingen an der Steige 1
Imola 1
London 1
Luxembourg 1
Mahé 1
Medesano 1
Modena 1
Molenbeek-Saint-Jean 1
Mumbai 1
Nanning 1
New Delhi 1
Ottawa 1
Paris 1
Piacenza 1
Prague 1
Totale 1897
Nome #
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 115
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 60
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 52
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 51
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 48
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 42
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 41
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 40
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 40
Survival predisction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 39
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. 39
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 38
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 36
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. 35
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 34
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. 34
p73 and p53 pathway in human breast cancers. 33
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 32
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 31
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 31
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 29
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 29
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 28
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 28
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI) 27
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 27
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 27
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 26
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 26
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 26
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 26
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 25
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 25
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 25
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 25
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 25
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 24
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 24
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 24
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 24
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 24
Role of Fcγ receptors in HER2-targeted breast cancer therapy 24
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 23
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study 23
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY 23
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 22
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 22
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer 22
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 22
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data 22
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 21
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 21
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 21
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 21
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 20
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 20
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 20
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 20
Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial 20
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 19
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) 19
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 19
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 19
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 19
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 19
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer 18
La gestione domiciliare del paziente oncologico 18
Osteooncologia 18
Sintomi "Segnale" in Oncologia Clinica 18
A review of immune checkpoint blockade in breast cancer 18
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 17
EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE REFRACTORY PROSTATE CARCINOMA 17
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 17
DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC) 17
My best choice after a round trip from illness 17
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 16
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC) 16
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 16
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 16
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy 16
Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables 16
Correlation between HER2/ neu amplification in fine needle aspirates from breast carcinoma and responses to neoadjuvant anthracycline based chemotherapy 16
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 16
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 15
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 15
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 15
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 15
BRCA1 status, molecular markers, clinical variables in breast cancer patients with high probability of having an inherited genetic mutation 15
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 15
p73 and p53 pathway in human breast cancers [9] 14
FCGR, Cetuximab, and Colorectal Cancer Survival-Letter 14
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 14
BRCA1 status, molecular markers and clinical variables in breast cancer (BC) with high probability of having an inherited cancer predisposing genetic mutation 14
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumabbased treatment in patients with HER2/ neupositive metastatic breast cancer 14
Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFRexpressing metastatic colorectal cancer patients treated with cetuximab based therapy 14
Early detection of recurrences in the followup of primary breast cancer in an asymptomatic or symptomatic phase 13
TAp73 and Delta Np73 expression and localization in breast cancer 13
Evidence for Linkage Disequilibrium Between Fc gamma RIIIaV158F and Fc gamma RIIaH131R Polymorphisms in White Patients, and for an Fc gamma RIIIaRestricted Influence on the Response to Therapeutic Antibodies IN REPLY 13
Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial 13
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 12
Totale 2457
Categoria #
all - tutte 6830
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6830


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201825 0000 00 23 31700
2018/201948 0101 129 32 41132
2019/2020690 3540142 2329 2310 263779021
2020/2021389 17441113 3125 4335 68127020
2021/2022637 23102428 1667 4043 412626293
2022/20231110 334200136183 2570 00 0000
Totale 2940